[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338151-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-338151-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","exploring-the-relationship-between-morphea-and-malignancy-a-decade-long-single-center-study-of-204-patients","Exploring the relationship between morphea and malignancy - a decade-long single-center study of 204 patients","","The study evaluates malignancy incidence and malignancy types among morphea patients and compares demographics, clinical features, treatments, and outcomes between patients with and without malignancy. A retrospective cohort of 204 morphea patients treated at Rabin Medical Center from 2012 to 2023 was analyzed, with cases stratified by malignancy timing relative to morphea diagnosis. Malignancies developed in 23% (47/204). Patients with malignancy were older, and all-cause mortality was higher, especially when malignancy followed morphea. Pre- and post-morphea malignancy patterns were also characterized, with skin, cervical, breast, and gastrointestinal and lung cancers most frequent.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-the-relationship-between-morphea-and-malignancy-a-decade-long-single-center-study-of-204-patients/338151/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-the-relationship-between-morphea-and-malignancy-a-decade-long-single-center-study-of-204-patients/338151.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the main purpose of the decade-long study on morphea and malignancy?","Question",{"text":62,"@type":63},"The study assesses the incidence and types of malignancies in morphea patients and compares characteristics and outcomes between patients with and without malignancy.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How many morphea patients developed malignancies in this cohort?",{"text":67,"@type":63},"Out of 204 patients, 47 (23%) developed malignancies during the study period.",{"name":69,"@type":60,"acceptedAnswer":70},"How did timing of malignancy relative to morphea affect mortality?",{"text":71,"@type":63},"Mortality was higher when malignancy occurred after morphea (26%) than when it preceded morphea (17.2%), and the malignancy group overall had higher all-cause mortality than those without malignancy.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},338151,1790990144,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Archives of Dermatological Research (2024) 316:611 [https://doi.org/10.1007/s00403-024-03357-7](https://doi.org/10.1007/s00403-024-03357-7)  \nORIGINAL PAPER  \nExploring the relationship between morphea and malignancy: a decade-long single-center study of 204 patients  \nKeren Lyakhovitsky1,2 · Giovanni Damiani3,4 · Daniel Mimouni1,2 · Anna Aronovich1,2  \nReceived: 20 July 2024 / Revised: 17 August 2024 / Accepted: 26 August 2024 / Published online: 11 September 2024 © The Author(s) 2024  \nAbstract  \nThe association between systemic scleroderma and malignancy is well-documented, but there is limited data on the relationship between morphea and malignancy. This study aims to assess the incidence and types of malignancies in morphea patients, comparing demographics, clinical characteristics, treatments, and outcomes between those with and without malignancy. We conducted a retrospective study of 204 morphea patients treated at Rabin Medical Center between 2012 and 2023. Data on demographics, clinical subtypes, comorbidities, treatments, and outcomes were collected. Patients were categorized based on malignancy status and the timing of malignancy relative to their morphea diagnosis. Among the 204 patients (154 women and 50 men, mean age 53.7 ±20 years), 47 (23%) developed malignancies. In 29 patients (61.7%), malignancy occurred before the onset of morphea; in 23 patients (48.9%), it occurred after morphea. Five patients (10.6%) had malignancies both before and after the diagnosis of morphea. Patients with malignancy were significantly older than those without (64.7 ± 15.1 years vs. 50.3 ±20 years, p \u003C0.0001) . The all-cause mortality rate was higher in the malignancy group compared to those without malignancy (23.4% vs. 3.8%, p = 0.00002) . Moreover, mortality was higher in patients whose malignancy occurred after morphea than in those whose malignancy preceded morphea (26% vs. 17.2%) . The most common post-morphea malignancies in our cohort included non-melanoma skin cancer, cervical cancer, breast cancer, stomach cancer, and lung cancer. The most common pre-morphea malignancies included breast cancer, non-melanoma skin cancer, colon cancer, prostate cancer, and testicular cancer. This study suggests potential associations between morphea and malignancies, influenced by patient age, sequence of diagnosis, and treatment regimens. Further control studies are needed to explore these relationships more definitively.  \nKeywords Localized scleroderma · Morphea · Mortality · Malignancy · Neoplasms  \n􀀍 AnnaAronovich[anaronovich@gmail.com](anaronovich@gmail.com)  \n1 Division of Dermatology, Rabin Medical Center, Petach Tikva, Israel  \n2 School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel  \n3 UOC Maxillofacial Surgery and Dentistry, Ospedale Maggiore Policlinico, Fondazione IRCCS Ca’ Granda, Milan, Italy  \n4 Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy  \nIntroduction  \nMorphea (localized scleroderma), a rare, chronic inflammatory connective tissue disorder that manifests with inflammation and fibrosis affecting the skin and underlying soft tissue, with possible extension to adjacent structures (e.g., lungs, gastrointestinal tract) [1]. Despite being primary recognized as a condition confined to the skin, some subtypes of morphea exhibit extra-cutaneous manifestations, involving the musculoskeletal and central nervous systems [1] . The annual incidence of morphea varies from 4 to 27 new cases per million, with approximately two-thirds occurring in adults [1] . There are two incidence peaks: between ages 2 to 14 and in the 5th decade of life [1]. Morphea predominantly affects females, with a female-to-male ratio of 4:1, and is most common among Caucasians, followed by Hispanics and Latin Americans [2] .  \nThe five main clinical types of morphea include limited, generalized, linear, deep, and mixed, with plaque-type and generalized morphea being prevale","cbCaiuysONKBXOXb","https://ap.wps.com/l/cbCaiuysONKBXOXb","pdf",1018022,"English","# Abstract\n# Introduction\n## Morphea overview\n## Clinical types and pathogenesis\n## Diagnosis and treatment\n## Morphea–malignancy association","[{\"question\":\"What is the main purpose of the decade-long study on morphea and malignancy?\",\"answer\":\"The study assesses the incidence and types of malignancies in morphea patients and compares characteristics and outcomes between patients with and without malignancy.\"},{\"question\":\"How many morphea patients developed malignancies in this cohort?\",\"answer\":\"Out of 204 patients, 47 (23%) developed malignancies during the study period.\"},{\"question\":\"How did timing of malignancy relative to morphea affect mortality?\",\"answer\":\"Mortality was higher when malignancy occurred after morphea (26%) than when it preceded morphea (17.2%), and the malignancy group overall had higher all-cause mortality than those without malignancy.\"}]","Exploring the relationship between morphea and malignancy - a decade-long single-center study of 204 patients | PDF",1790022225,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8996c49ab4e05cb4f411f12d500b4a30.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffd26d3441f299f7b954033ee55e394f.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e57065d916f343f71e59f8b332830a64.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e28482499cc15310fcea4544108e8421.webp",980,1301]